CD7-targeted CAR-T cells (Xuzhou Medical University)

CD7-targeted CAR-T cells (Xuzhou Medical University) is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of relapsed or refractory severe aplastic anemia (SAA). The therapy involves collecting a patient's own T cells, which are then genetically engineered using a retroviral vector to express a CAR specific for the CD7 antigen. CD7 is a marker found on early T-lineage cells and is involved in the immune-mediated destruction of hematopoietic stem and progenitor cells (HSPCs) that characterizes SAA. By targeting and eliminating these pathogenic CD7-positive T cells, the therapy aims to suppress marrow destruction and facilitate the restoration of normal hematopoiesis. This approach is currently being evaluated in exploratory clinical trials to assess safety, molecular changes, and preliminary efficacy in patients who have failed standard immunosuppressive therapy or lack suitable transplant donors.

Other names

autologous CD7-specific CAR-T cellsCD7 CAR-T cells infusionCD-7 CAR-T cells infusionCD 7 CAR-T cells infusion